B. Riley Issues Negative Forecast for Lantheus Earnings

Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) - Stock analysts at B. Riley reduced their Q3 2025 EPS estimates for Lantheus in a research note issued to investors on Thursday, March 20th. B. Riley analyst Y. Zhi now anticipates that the medical equipment provider will post earnings of $1.51 per share for the quarter, down from their prior estimate of $1.57. B. Riley has a "Buy" rating and a $122.00 price target on the stock. The consensus estimate for Lantheus' current full-year earnings is $6.01 per share.

Several other brokerages have also recently commented on LNTH. JMP Securities reiterated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Stock Down 1.4 %

LNTH stock traded down $1.39 during trading on Monday, hitting $97.04. The company had a trading volume of 681,764 shares, compared to its average volume of 930,255. The stock has a market cap of $6.65 billion, a price-to-earnings ratio of 16.15 and a beta of 0.38. The firm has a 50-day moving average price of $93.01 and a 200-day moving average price of $96.47. Lantheus has a 12 month low of $58.16 and a 12 month high of $126.89.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the 3rd quarter worth about $25,955,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after acquiring an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new position in shares of Lantheus during the 4th quarter worth approximately $323,000. Finally, Focus Financial Network Inc. bought a new position in shares of Lantheus in the fourth quarter worth $292,000. Institutional investors own 99.06% of the company's stock.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.